Lord, Abbett & Co
TMCI icon

Lord, Abbett & Co’s Treace Medical Concepts TMCI Stock Holding History

Lord, Abbett & Co’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-388,080
Closed -$9.93M – 584
2023
Q2 		$9.93M Buy
388,080
+95,619
+33% +$2.47M 0.03% 419
2023
Q1 		$7.37M Sell
292,461
-239,645
-45% -$5.63M 0.03% 436
2022
Q4 		$12.2M Buy
532,106
+1,761
+0.3% +$40.5K 0.04% 405
2022
Q3 		$11.7M Buy
530,345
+31,812
+6% +$615K 0.04% 383
2022
Q2 		$7.15M Buy
498,533
+34,002
+7% +$573K 0.03% 446
2022
Q1 		$8.78M Buy
464,531
+193,623
+71% +$3.76M 0.02% 477
2021
Q4 		$5.05M Sell
270,908
-2,624
-1% -$54.2K 0.01% 552
2021
Q3 		$7.36M Buy
273,532
+115,807
+73% +$3.19M 0.02% 559
2021
Q2 		$4.93M Buy
+157,725
New +$5.02M 0.01% 610

Other funds holding TMCI

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's TMCI Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Treace Medical Concepts (TMCI) in Q3 2023, closing a stake of 388,080 shares — an estimated $9.93M sold.

Lord, Abbett & Co first reported a position in TMCI in Q2 2021 and held it in 9 quarters. The position peaked at $12.2M in Q4 2022. 123 funds tracked by Wall St. Rank hold TMCI as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Treace Medical Concepts position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 388,080 Treace Medical Concepts shares in Q3 2023, an estimated $9.93M.
  • Lord, Abbett & Co first reported a position in Treace Medical Concepts in Q2 2021 and held it in 9 quarters.
  • Lord, Abbett & Co's Treace Medical Concepts position peaked at $12.2M in Q4 2022.
  • 123 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.